Join Dr. Art Hsing-Mao Chu, CEO of T-E Meds, at World ADC San Diego 2024 on Nov 4th to hear more about our breakthrough technology.
Join Dr. Kun-Po Li, the Director of Business Development of T-E Meds, to present our novel ADC technology (Poster Number: 84).
This breakthrough technology features dual-payloads and a high drug-to-antibody ratio (DAR), demonstrating superior efficacy in both in vitro and in vivo models. We look forward to connecting at the event! Partnering opportunities are welcome.
